Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program

NCT05066685 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05066685
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05066685 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characteristics of Patients With Neovascular Age-related Macular Degeneration Enrolled in the Brolucizumab Patient Support Services Program
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
August 11, 2020
Completion date
September 25, 2020
Enrollment
18,457 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd)